Prolonged survival after diagnosis of brain metastasis from XXXX : contributing factors and treatment implications.

@entity1 @entity5 @entity0 @entity1722
OBJECTIVE: The prognosis of @entity0 -derived brain metastasis is poor, but new drugs and recent therapeutic strategies have helped extend survival in @entity1 . Prediction of therapeutic responses and outcomes is not yet possible, however. In a retrospective study, we examined prognostic factors in @entity1 with @entity0 -derived brain metastasis, and we tested the prognostic utility of a @entity0 -specific Graded Prognostic Assessment in these @entity1 . METHODS: Sixty-three @entity1 diagnosed with brain metastasis from @entity0 treated surgically and adjuvantly were included. We examined clinical variables per @entity5 subtype: ER+/ @entity1722 - (luminal), @entity1722 + ( @entity1 epidermal growth factor receptor type 2-enriched) or ER-/PR-/ @entity1722 - (triple negative). We also categorized @entity1 ' @entity0 -specific Graded Prognostic Assessment scores and analyzed post-brain metastasis survival time in relation to these categories. RESULTS: The @entity0 comprised the following subtypes: luminal, n = 18; @entity1 epidermal growth factor receptor type 2-enriched, n = 27 and triple-negative, n = 18; median survival per subtype was 11, 37 and 3 months, respectively. Survival of @entity1 epidermal growth factor receptor type 2-enriched @entity1 was longer, though not significantly (P = 0.188), than that of luminal @entity1 . Survival of triple-negative @entity1 was significantly short (vs. @entity1 epidermal growth factor receptor type 2-enriched @entity1 , P < 0.001). Karnofsky performance status, @entity1722 status and the disease-free interval (from initial treatment to first recurrence) were shown to be significant prognostic factors (Karnofsky performance status < 70: relative risk 2.08, P = 0.028; @entity1722 +: relative risk 2.911, P = 0.004; disease-free interval < 24 months: relative risk 1.933, P = 0.011). @entity0 -specific Graded Prognostic Assessment scores reflected disease-free intervals and survival times. CONCLUSIONS: Our data indicate that @entity0 -specific Graded Prognostic Assessment-based prediction will be helpful in determining appropriate therapeutic strategies for @entity1 with brain metastasis from @entity0 .
